Jun. 23 at 1:51 PM
$PHAR Rare diseases rarely receive as much attention as larger therapeutic areas, despite their complexity, patient impact, and limited treatment options. This is precisely where Pharming Group focus its efforts.
At the recent Jefferies Global Healthcare Conference in New York, CEO Fabrice Chouraqui highlighted Pharming’s growth drivers and key strategic milestones. With two commercial products, RUCONEST® and Joenja® (leniolisib), on the market, Joenja® expanding internationally, and multiple clinical studies underway, Pharming continues to evolve beyond its origins as a single-product rare disease company, strengthening its foundation for long-term growth.
Recent international regulatory progress, pediatric expansion efforts in the U.S., and ongoing clinical pipeline development build on this momentum, reinforcing Pharming’s position as a growing rare disease company with an extending global footprint .
